Afatinib enters Phase III in head and neck cancer; expects to file in 2-3 years
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is progressing its head and neck cancer programme with the start of two global Phase III trials for its irreversible EGFR inhibitor, afatinib, investigating the product in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.